Ginkgo Bioworks Holdings, Inc., formerly Spinning Eagle Acquisition Corp, is engaged in building a platform to program cells. The Company's platform is used to program cells on behalf of its customers. Its cell programs are designed to enable biological production of products such as therapeutics, key food ingredients, and chemicals derived from petroleum. The Company's platform is used to design, write, and debug deoxyribonucleic acid (DNA) code in engineered organisms to execute programs for its customers. The Company’s platform comprises of equipment, robotic automation, software, data pipelines and tools, and standard operating procedures for genetic engineering, fermentation, and analytics, a library of proprietary genetic assets and associated performance data; and developers and operators of the foundry and codebase. It serves industries, including chemicals, agriculture, food, consumer products, and pharmaceuticals.
52 Week high
52 Week low
PRNewsWire • 3 days ago • DNAEnsovi Leverages Ginkgo Enzyme Services to Optimize Cell-Free Carbon Fixation Process for Biomanufacturing
The Motley Fool • 4 days ago • DNAWhy Ginkgo Bioworks Stock Is Surging Higher Today
The Motley Fool • 4 days ago • DNAThese 2 Stocks Are Getting Smart Investors' Attention Wednesday
InvestorPlace • 4 days ago • DNADNA Stock Alert: Ginkgo Bioworks Announces Major Partnership With Pfizer
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.